Edesa Biotech (EDSA) Competitors $1.73 -0.02 (-1.14%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends EDSA vs. AKTX, SNTI, EQ, CMMB, INKT, LSB, CLDI, PULM, ATHA, and LSTAShould you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include Akari Therapeutics (AKTX), Senti Biosciences (SNTI), Equillium (EQ), Chemomab Therapeutics (CMMB), MiNK Therapeutics (INKT), Lakeshore Biopharma (LSB), Calidi Biotherapeutics (CLDI), Pulmatrix (PULM), Athira Pharma (ATHA), and Lisata Therapeutics (LSTA). These companies are all part of the "pharmaceutical products" industry. Edesa Biotech vs. Akari Therapeutics Senti Biosciences Equillium Chemomab Therapeutics MiNK Therapeutics Lakeshore Biopharma Calidi Biotherapeutics Pulmatrix Athira Pharma Lisata Therapeutics Edesa Biotech (NASDAQ:EDSA) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, community ranking, media sentiment, profitability, valuation and dividends. Does the media prefer EDSA or AKTX? In the previous week, Akari Therapeutics had 2 more articles in the media than Edesa Biotech. MarketBeat recorded 3 mentions for Akari Therapeutics and 1 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 0.80 beat Akari Therapeutics' score of 0.25 indicating that Edesa Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edesa Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akari Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer EDSA or AKTX? Edesa Biotech presently has a consensus target price of $21.00, indicating a potential upside of 1,113.87%. Given Edesa Biotech's stronger consensus rating and higher possible upside, research analysts plainly believe Edesa Biotech is more favorable than Akari Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edesa Biotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Akari Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, EDSA or AKTX? Edesa Biotech has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Akari Therapeutics has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Do institutionals and insiders believe in EDSA or AKTX? 5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 25.0% of Edesa Biotech shares are held by company insiders. Comparatively, 38.9% of Akari Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community believe in EDSA or AKTX? Akari Therapeutics received 235 more outperform votes than Edesa Biotech when rated by MarketBeat users. However, 77.14% of users gave Edesa Biotech an outperform vote while only 51.68% of users gave Akari Therapeutics an outperform vote. CompanyUnderperformOutperformEdesa BiotechOutperform Votes2777.14% Underperform Votes822.86% Akari TherapeuticsOutperform Votes26251.68% Underperform Votes24548.32% Which has stronger valuation & earnings, EDSA or AKTX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdesa BiotechN/AN/A-$8.37M-$1.93-0.90Akari TherapeuticsN/AN/A-$10.01MN/AN/A Is EDSA or AKTX more profitable? Akari Therapeutics' return on equity of 0.00% beat Edesa Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Edesa BiotechN/A -137.95% -97.48% Akari Therapeutics N/A N/A N/A SummaryEdesa Biotech beats Akari Therapeutics on 7 of the 13 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Edesa Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDSA vs. The Competition Export to ExcelMetricEdesa BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.07M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-0.9010.5989.9717.18Price / SalesN/A195.801,116.21116.99Price / CashN/A57.1642.8937.86Price / Book0.745.094.784.78Net Income-$8.37M$151.83M$120.23M$225.60M7 Day Performance-10.65%-2.13%-1.92%-1.23%1 Month Performance-18.01%-3.10%11.49%3.36%1 Year Performance-64.11%11.54%30.57%16.60% Edesa Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDSAEdesa Biotech3.554 of 5 stars$1.73-1.1%$21.00+1,113.9%-64.5%$6.07MN/A-0.9020Earnings ReportPositive NewsGap DownAKTXAkari TherapeuticsN/A$0.98+0.7%N/A-67.2%$24.27MN/A0.009Analyst ForecastGap DownHigh Trading VolumeSNTISenti Biosciences2.3392 of 5 stars$5.24-5.9%$10.00+90.8%-5.2%$24.05M$2.56M-0.334News CoverageGap DownEQEquillium2.9048 of 5 stars$0.66-6.0%$5.00+654.8%-16.5%$23.47M$45.91M-5.0440Gap DownCMMBChemomab Therapeutics3.3163 of 5 stars$1.62+2.8%$7.33+351.6%+230.1%$23.32MN/A-1.5820Positive NewsINKTMiNK Therapeutics2.2354 of 5 stars$0.59-4.5%$6.50+1,005.1%-47.6%$23.26MN/A-1.4930Gap UpLSBLakeshore Biopharma0.4967 of 5 stars$2.49flatN/AN/A$23.18M$80.82M0.00773News CoverageGap UpCLDICalidi Biotherapeutics2.039 of 5 stars$1.77-4.3%$16.67+841.6%N/A$23.15M$50,000.000.0041News CoverageGap DownPULMPulmatrix0.1923 of 5 stars$6.08+5.7%N/A+209.2%$22.19M$7.30M-2.1820Analyst ForecastNews CoverageATHAAthira Pharma2.111 of 5 stars$0.57-3.0%$13.83+2,337.6%-72.6%$21.95MN/A-0.2140LSTALisata Therapeutics1.9029 of 5 stars$2.61+1.2%$15.00+474.7%-5.4%$21.91MN/A-1.1030 Related Companies and Tools Related Companies AKTX Competitors SNTI Competitors EQ Competitors CMMB Competitors INKT Competitors LSB Competitors CLDI Competitors PULM Competitors ATHA Competitors LSTA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EDSA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edesa Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edesa Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EDSA Stock Alerts